Brazil’s Semaglutide Patent Expiry: A Turning Point for Domestic Pharmaceutical Competitiveness
The expiration of the semaglutide patent in Brazil is catalyzing a shift in the country’s pharmaceutical landscape, enabling local manufacturers to produce biosimilar alternatives to global blockbusters like Novo Nordisk’s Ozempic. This development not only promises enhanced drug accessibility but also signals a maturation of Brazil’s pharmaceutical industry amid growing global competition.